unpreced
move
initi
collabor
multicent
research
project
identifi
caus
agent
sar
avian
influenza
quickli
rule
sever
laboratori
diagnos
activ
infect
chlamydia
paramyxovirus
somebut
far
allpati
suffer
sar
howev
good
evid
neither
plausibl
etiolog
agent
novel
infecti
diseas
network
compris
laboratori
access
sar
patient
sampl
particular
expertis
emerg
respiratori
virus
sever
week
spirit
cooper
rather
competit
prevail
sampl
exchang
result
find
share
continu
via
daili
telephon
confer
passwordprotect
websit
within
week
group
hong
kong
germani
canada
unit
state
america
found
hitherto
unknown
member
coronaviru
famili
sar
patient
achiev
independ
studi
certainli
benefit
greatli
realtim
share
interim
result
although
differ
approach
employ
includ
cell
cultur
electron
microscopi
molecular
techniqu
sequenc
data
show
laboratori
identifi
coronaviru
previous
unknown
human
veterinari
virolog
figur
shown
sar
patient
seroconvert
viru
cours
ill
healthi
unexpos
control
individu
lack
antibodi
reactiv
howev
remain
proven
novel
coronaviru
inde
etiolog
agent
sar
rather
innoc
bystand
newli
discov
thorough
studi
experiment
infect
macaqu
newli
isol
agent
shown
caus
sarslik
ill
subsequ
reisol
agent
koch
postul
fulfil
april
offici
announc
provision
term
sarsassoci
coronaviru
sarscov
caus
agent
sar
base
breakthrough
test
detect
viral
sequenc
specif
antibodi
quickli
develop
made
avail
affect
countri
addit
numer
scientist
embark
programm
develop
vaccin
drug
antibodi
prophylact
therapeut
use
within
month
sar
outbreak
brought
control
juli
declar
last
chain
persontoperson
transmiss
interrupt
measur
includ
sourc
isol
patientswho
becam
infecti
onset
clinic
symptomsstrict
infect
control
health
care
facil
time
identif
quarantin
expos
contact
perhap
also
measur
increas
social
distanc
travel
warn
screen
travel
led
remark
remark
rapid
success
thorough
consist
implement
measur
eventu
brought
end
sar
outbreak
even
worst
affect
area
meantim
howev
sever
areasdiffer
chines
provinc
guangdong
promin
capit
beij
also
toronto
canada
taiwanpaid
high
price
implement
adequ
countermeasur
time
fashion
typic
socal
superspread
highli
contagi
sar
patient
would
seek
treatment
poorli
prepar
facil
time
danger
realiz
score
staff
patient
becom
infect
becom
sourc
spread
interestingli
despit
rapid
identif
agent
laboratori
test
becom
avail
almost
immedi
formid
achiev
contribut
much
contain
outbreak
instead
prudent
thorough
use
oldfashion
measur
isol
quarantin
prove
key
success
identif
suspect
case
base
clinic
epidemiolog
criteria
high
fever
c
plu
symptom
respiratori
tract
infect
plu
exposur
histori
detail
depend
locat
sar
statu
time
addit
posit
sarscov
test
result
radiolog
patholog
evid
pneumonia
respiratori
distress
syndrom
would
make
probabl
case
final
case
count
novemb
juli
death
sinc
sar
reappear
four
occas
three
involv
laboratoryacquir
infect
demonstr
danger
breach
biosafeti
procedur
risk
subsequ
spread
commun
secondari
transmiss
outsid
laboratori
fourth
sar
outbreak
due
reintroduct
reservoir
minim
risk
reemerg
issu
guidelin
surveil
possibl
sar
case
risk
categori
guid
adequ
nation
surveil
strategi
guard
possibl
emerg
sar
emerg
wildlif
anim
reservoir
emerg
introduct
laboratori
via
intern
travel
low
risk
sarscov
emerg
introduct
also
urg
countri
conduct
inventori
laboratori
work
store
sarscov
ensur
strict
enforc
biosafeti
procedur
sar
two
coronavirus
e
known
infect
human
caus
rel
minor
diseas
difficult
propag
laboratori
receiv
rel
littl
attent
diagnost
research
laboratori
contrast
sever
coronavirus
recogn
anim
pathogen
infect
pig
dog
rabbit
cat
mice
rat
turkey
chicken
time
play
import
role
veterinari
medicin
obviou
major
human
sar
case
acquir
transmiss
sar
suffer
prove
key
eventu
control
howev
seem
highli
unlik
previous
exist
diseas
entiti
recogn
propens
caus
nosocomi
outbreak
often
hospit
set
would
overlook
long
first
sar
case
identifi
retrospect
variou
local
guangdong
provinc
first
earli
case
occur
foshan
novemb
sever
follow
week
nearbi
place
interest
soon
focus
earli
index
case
characterist
patient
common
could
point
sourc
sarscov
infect
inde
mani
earli
index
patient
either
work
kitchen
market
live
nearbi
constantli
expos
multitud
speci
domest
wild
anim
trade
kept
captiv
final
slaughter
prepar
consumpt
provid
impetu
studi
anim
sold
guangdong
market
infect
coronavirus
close
relat
sarscov
identifi
differ
speci
commonli
mask
palm
civet
paguma
larvata
also
chines
ferret
badger
melogal
moschata
raccoon
dog
nyctereut
procyonoid
small
sar
outbreak
occur
guangdong
late
molecular
analysi
viru
isol
human
case
anim
sampl
place
time
confirm
zoonot
acquir
paguma
larvata
howev
investig
reveal
wide
consum
speci
like
anim
reservoir
popul
studi
uninfect
later
research
identifi
multitud
coronavirus
differ
speci
bat
asia
elsewher
among
probabl
progenitor
sarscov
studi
differ
group
demonstr
sar
result
spillov
wildlif
reservoirmost
like
batsinto
intermedi
host
host
importantli
paguma
larvata
human
popul
rapid
viral
evolut
demonstr
like
pivot
factor
allow
sarscov
rapidli
adapt
nonreservoir
speci
tabl
show
distribut
sever
differ
coronavirus
human
anim
classif
differ
group
diseas
caus
sarscov
may
present
rather
nonspecif
clinic
sign
symptom
differenti
diagnosi
therefor
wide
may
includ
variou
common
respiratori
pathogen
includ
influenza
parainfluenza
respiratori
syncyti
virus
rsv
laboratori
diagnosi
sar
remain
challeng
fact
despit
rapid
identif
sarscov
etiolog
agent
test
contribut
littl
success
control
outbreak
insuffici
test
specif
occas
caus
falseposit
result
lead
consider
confus
mani
viral
diseas
viru
shed
greatest
earli
symptomat
phase
around
immedi
follow
onset
symptom
unfortun
viru
excret
compar
low
initi
phase
sar
peak
respiratori
specimen
stool
around
day
onset
clinic
ill
addit
current
laboratori
test
avail
reliabl
diagnos
sar
first
day
ill
highest
test
sensit
achiev
bronchoalveolar
lavag
fluid
lung
biopsi
tissu
onset
ill
invas
procedur
associ
risk
transmiss
nasopharyng
aspir
throat
wash
taken
respiratori
precaut
preserv
viral
transport
medium
remain
import
diagnost
specimen
commonli
viral
genom
detect
usual
revers
transcriptasepolymeras
chain
reaction
rtpcr
use
diagnost
nucleic
acid
amplif
test
design
target
nucleoprotein
gene
clearli
proven
clinic
studi
superior
realtim
rtpcr
nasopharyng
aspir
sensit
rapid
method
furthermor
determin
viral
load
nasopharyng
specimen
serum
shown
clinic
valu
import
prognost
factor
avoid
falseposit
result
stipul
follow
test
least
two
differ
clinic
specimen
type
eg
nasopharyng
aspir
stool
type
clinic
specimen
collect
least
two
occas
cours
ill
eg
sequenti
nasopharyng
aspir
origin
clinic
sampl
two
differ
assay
repeat
assay
use
new
rna
extract
test
sarscov
cultiv
vero
cell
respiratori
materi
also
fecal
sampl
figur
isol
viru
must
identifi
sarscov
use
test
cell
cultur
demand
test
current
except
anim
trial
mean
show
exist
live
viru
antigen
detect
respiratori
fecal
specimen
use
enzym
immunoassay
eia
gener
less
sensit
rtpcr
howev
antigen
detect
serum
specimen
monoclon
antibodi
monospecif
polyclon
antibodi
viral
n
protein
found
sensit
specif
test
diagnosi
sar
serum
antibodi
level
start
rise
day
onset
ill
sensit
serum
antigen
assay
progress
decreas
day
antibodi
test
allow
indirect
diagnosi
sarscov
infect
unsuit
acut
ill
posit
antibodi
test
result
indic
previou
infect
sarscov
seroconvers
neg
posit
fourfold
rise
antibodi
titer
acut
convalesc
serum
indic
recent
infect
neg
antibodi
test
result
later
day
onset
ill
like
indic
infect
sarscov
taken
place
virusspecif
serum
igg
igm
iga
antibodi
sarscov
appear
around
time
day
onset
symptom
antibodi
test
therefor
gener
use
first
week
ill
antibodi
test
indirect
immunofluoresc
antibodi
test
commonli
perform
neutral
antibodi
test
cell
cultur
requir
biosafeti
level
laboratori
figur
recombin
nucleocapsid
eia
may
use
rapid
screen
test
possess
higher
sensit
detect
earli
day
onset
ill
singl
lowtit
posit
antibodi
result
due
crossreact
human
coronavirus
requir
confirm
specif
western
blot
neutral
assay
regard
seroconvers
least
fourfold
rise
antibodi
titer
acut
convalesc
serum
proof
infect
updat
guidelin
global
surveil
sar
octob
replac
previou
guidanc
sar
surveil
respons
one
key
recommend
independ
test
use
strongli
recommend
interepidem
period
countri
seek
verif
laboratoryconfirm
case
sar
preliminari
posit
case
prefer
extern
laboratori
part
sar
intern
refer
verif
laboratori
network
figur
human
sarscov
longer
circul
human
popul
nevertheless
viru
still
present
anim
reservoir
virolog
laboratori
reemerg
anytim
singl
test
use
diagnos
sar
reason
degre
accuraci
diagnosi
therefor
continu
reli
clinic
examin
support
case
definit
includ
risk
assess
accord
updat
guidelin
tabl
initi
symptom
sar
nonspecif
complic
differenti
diagnosi
mean
incub
period
day
rang
day
although
isol
report
longer
incub
period
unlik
influenza
viru
patient
infecti
first
day
ill
transmiss
symptomat
sar
patient
usual
occur
fifth
day
onset
diseas
line
rise
viral
load
nasopharyng
secret
peak
around
day
report
transmiss
occur
onset
symptom
typic
clinic
present
sar
viral
pneumonia
rapid
respiratori
deterior
patient
initi
develop
influenzalik
prodrom
symptom
fever
malais
myalgia
headach
rigor
nonproduct
cough
major
present
symptom
wherea
rhinorrhea
sore
throat
less
frequent
seen
clinic
deterior
often
accompani
wateri
diarrhea
commonli
occur
week
onset
ill
although
histori
fever
frequent
report
symptom
may
absent
initi
measur
sever
case
develop
rapidli
progress
respiratori
distress
oxygen
desatur
approxim
requir
intens
care
chest
radiograph
typic
show
groundglass
opac
focal
consolid
especi
peripheri
subpleur
region
lower
zone
progress
involv
lung
uncommon
featur
later
stage
sometim
includ
spontan
pneumothorax
pneumomediastinum
subpleur
fibrosi
cystic
chang
nosocomi
transmiss
sarscov
strike
featur
sar
outbreak
major
case
occur
adult
children
less
commonli
affect
adult
usual
milder
ill
overal
mortal
rate
approxim
age
presenc
comorbid
poor
prognost
indic
although
sar
outbreak
still
ongo
first
half
signific
fund
made
avail
sarsrel
research
immunomodul
ie
corticosteroid
intraven
immunoglobulin
thymosin
antitnf
empir
use
treatment
sar
initi
epidem
correl
viral
load
clinic
outcom
suggest
suppress
viral
replic
effect
antivir
drug
key
prevent
morbid
mortal
numer
potenti
antivir
agent
identifi
use
differ
approach
vitro
suscept
test
result
demonstr
ifnalpha
ifnbeta
potenti
activ
ribavirin
good
activ
test
human
cell
despit
lack
activ
vero
cell
viral
proteas
import
target
develop
antivir
drug
proteas
inhibitor
like
nelfinavir
glycyrrhizin
chloroquin
mani
other
well
mani
herbal
formul
found
possess
antivir
activ
sarscov
vitro
addit
use
nitric
oxid
snitronacetylpenicillamin
inhal
experiment
form
rescu
therapi
sar
appear
inhibitori
activ
sarscov
screen
chemic
librari
identifi
sever
inhibitor
viral
proteas
helicas
identif
angiotensinconvert
enzym
obligatori
cellular
receptor
tabl
risk
categori
emerg
sar
emerg
sarscovlik
virus
wildlif
anim
reservoir
countriesarea
identifi
sourc
epidem
southern
china
area
increas
likelihood
animaltohuman
transmiss
sarscovlik
virus
wildlif
anim
reservoir
emerg
introduct
sarscov
laboratori
intern
travel
countriesarea
potenti
higher
risk
sarscov
emerg
introduct
due
presenc
laboratori
sarscov
sarscovlik
virus
studi
clinic
specimen
infect
sarscov
process
store
countriesarea
entri
larg
number
person
area
wildlif
anim
reservoir
sarscovlik
virus
found
low
risk
sarscov
emerg
introduct
countriesarea
never
report
case
report
import
case
epidem
conduct
research
use
live
sarscovlik
virus
store
clinic
sampl
sar
case
sarscov
contribut
understand
sarscov
entri
process
help
character
two
target
antivir
therapeut
sarscov
spike
protein
howev
chemic
approach
evalu
human
anim
model
variou
approach
toward
produc
vaccin
sar
pursu
includ
use
inactiv
sarscov
plasmid
dna
adenoviru
vector
one
obviou
problem
vaccin
would
face
given
absenc
sarscov
transmiss
howev
wait
renew
outbreak
occur
commenc
vaccin
mean
preciou
week
would
lost
individu
risk
becom
immun
administr
preform
antibodi
obtain
human
anim
donor
recent
produc
vitro
effect
prevent
number
differ
infect
hepat
b
varicella
rsv
similarli
could
shown
neutral
antibodi
sarscov
protect
experiment
anim
infect
use
screen
larg
naiv
antibodi
librari
antibodi
phage
display
technolog
neutral
antibodi
identifi
produc
protect
vitro
evid
enhanc
sarscov
infect
subneutr
concentr
antibodi
immun
escap
mutant
gener
theori
could
ideal
tool
suffici
stock
human
monoclon
antibodi
could
procur
would
readi
use
wherev
sar
reemerg
one
could
passiv
immun
anyon
contact
sourc
patient
afford
immedi
protect
summari
sar
novel
sever
infecti
diseas
presum
origin
guangdong
southern
china
largescal
wildlif
trade
consumpt
favor
emerg
zoonosi
hitherto
unrecogn
anim
reservoir
zoonot
origin
new
agent
quickli
spread
within
human
popul
transmit
mostli
via
respiratori
rout
close
humantohuman
contact
sar
rapidli
dissemin
via
metropoli
hong
kong
intern
air
travel
import
potenti
nosocomi
transmiss
commun
hospit
soon
recogn
allow
appropri
measur
institut
place
unpreced
rapid
gain
knowledg
global
network
intern
collabor
led
unfortun
took
major
outbreak
affect
industri
countri
modern
health
care
system
first
sar
epidem
control
thu
end
rapid
success
achiev
tradit
sanitari
measur
mainli
rapid
identif
suspect
case
isol
diseas
fortun
sarscov
hasat
least
farnot
establish
perman
human
popul
rel
low
transmiss
except
superspread
led
low
basic
reproduct
number
r
togeth
fact
infect
individu
becom
infecti
develop
clinic
diseas
made
tradit
public
health
measur
effect
fact
first
pandem
twentyfirst
centuri
quickli
contain
reason
take
comfort
knowledg
histori
humankind
reach
phase
biomed
scienc
inform
technolog
abl
deal
threat
probabl
first
rapid
success
remark
unfortun
though
reflect
prepared
donald
burk
propos
follow
criteria
identifi
viru
famili
high
pandem
risk
caus
pandem
human
popul
recent
past
proven
abil
caus
larger
epizoot
intrins
propens
rapidli
undergo
evolut
basi
high
mutat
rate
genom
organ
favor
recombin
intrins
evolv
interestingli
even
sar
outbreak
obvious
fulfil
first
criterion
coronaviru
famili
clearli
regard
high
risk
start
late
porcin
epidem
diarrhea
coronaviru
pedv
caus
sever
swine
epizoot
europ
asia
second
criterion
high
evolv
coronaviru
famili
also
demonstr
porcin
respiratori
coronaviru
prcv
evolv
delet
mutat
gene
transmiss
gastroenter
viru
tgev
mutant
differ
tissu
tropism
less
virul
second
infecti
diseas
emerg
zoonot
sourc
wellrecogn
threat
long
sar
nevertheless
took
anotherfortun
minor
sar
outbreak
decis
step
taken
control
least
trade
directli
implic
paguma
larvata
southern
china
start
shortli
sar
control
anoth
agent
pandem
potenti
caus
ongo
epizoot
unpreced
proport
highli
pathogen
influenza
viru
transmiss
human
occur
almost
exclus
close
contact
infectedand
sickpoultri
despit
possibl
avian
influenza
viru
becom
fulli
human
trigger
next
influenza
pandem
even
activ
recogn
high
risk
wet
market
mostli
curtail
final
lesson
sarsparticularli
experi
beij
toronto
taiwan
suffer
devast
sar
outbreak
later
phase
outbreakemphas
enorm
import
open
time
commun
time
may
mean
admit
problem
least
initi
reflect
neg
countri
territori
concern
medium
long
term
howev
open
way
prevent
consequ
would
much
wors
although
wide
accept
wake
sar
experi
strong
influenc
new
intern
health
regul
enter
forc
june
inform
polici
countri
epizoot
unfortun
attest
notwithstand
grave
consequ
humanitarian
polit
econom
term
sar
serv
exampl
achiev
intern
cooper
modern
scienc
rigor
use
tradit
approach
even
prudent
precaut
suddenli
adopt
sar
certainli
last
highli
pathogen
novel
infecti
agent
cross
speci
barrier
human
popul
although
bat
must
high
list
culprit
emerg
viral
diseas
identifi
reservoir
host
number
emerg
virus
reason
group
anim
figur
promin
futur
mechan
behind
emerg
studi
may
link
agent
new
host
speci
ie
human
be
certain
case
also
intermedi
host
connect
mani
factor
determin
diseas
emerg
relat
human
activ
although
accompani
humankind
throughout
histori
fact
may
help
shape
human
histori
speed
extent
humaninduc
chang
acceler
markedli
recent
time
although
case
sar
peopl
lucki
end
may
quit
differ
next
time
round
import
improv
understand
emerg
minim
risk
natur
phenomenon
much
aggrav
human
behavior
